This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Learn about the efficacy and safety of Somavert, its tumour impact and its effect on co-morbidity management through clinical and real world data
Learn about funding and reimbursement for England, Scotland, Wales and Northern Ireland
Scroll through our resources about acromegaly management, patient resources, and experience with acromegaly
Menu
Close
Advice and support services to help you and your patients optimise your experience with Somavert about the efficacy and safety of Somavert through clinical and real world data
Click here for Somavert® (pegvisomant) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.
AcroQoL: Acromegaly Quality of Life Questionnaire
Utilise the AcroQoL survey to understand your acromegaly patients’ quality of life
History
The original AcroQoL survey was developed in 2001 by Dr. X. Badía and colleagues.1,2 With acromegaly being a disease having considerable impact on quality of life (QoL), an instrument to assess QoL in people with this disease can be helpful to provide clinicians with an effective means to assess patients’ self-perceived status as well as to screen patients who require appropriate further evaluation.2
Overview
The AcroQoL survey available to download here replicates the original survey and was designed in 2023 by Dr. Xavier Badía, Partner & CEO Omakase Consulting, and Prof. Susan Webb, Emeritus Professor Universitat Autònoma de Barcelona, IIB-SPau, and its creation was funded by Pfizer Ltd.
This digital survey is intended for acromegaly patients and provides the opportunity for these patients to have a better understanding of their quality of life which can be relayed back to their healthcare professional. This version of the AcroQoL Survey has been designed with back-end coding, meaning QoL scores are produced automatically, removing the need for manual adding-up. It is more user friendly with a reduction in time to complete the questionnaire.
Please download the survey and do NOT show it directly to patients from this website, which is intended for UK healthcare professionals only. The survey is for digital use only. Should you have any questions, please reach out to your local Pfizer representative.
The goal of this survey is to support healthcare professionals in confirming the impact of the disease and its treatment on patients’ quality of life.2
Download the digital survey to share with your acromegaly patients:
Download
How the survey works
The survey includes 22 questions that correlated to some of the complications that acromegaly patients can experience when suffering from the illness.2
Based on the answers to the 22 questions the digital survey will automatically produce quality of life (QoL) scores, broken down into the following:2
To ensure the scores best represent the patient please encourage them to answer all questions and understand there are no right or wrong questions.
Interpreting the results
When a patient completes the survey, please encourage them to share the results back with you.
The scores can be interpreted as follows:
Very poor Quality of Life Score: equal to, or less than, 40%.
Moderate Quality of Life Score: more than 40% and equal to or less than 60%.
Good Quality of Life Score: more than 60% and equal to or less than 100%.
Additional details on interpretation of the scores can be found at the bottom of the survey itself.
Sharing the survey with your patients
Please download the survey and do NOT show it directly to patients from this website, which is intended for UK healthcare professionals only.
The survey is for digital use only. Should you have any questions, please reach out to your local Pfizer representative.
To find out more about supporting your patients or to order starter kits
Somavert dosing
To find out more about supporting your patients or to order starter kits
Learn more
Using Somavert
Discover how patients can incorporate using Somavert into their routine
Learn more
References
Webb SM, Prieto L, Badia X, Albareda M, Catalá M, Gaztambide S, Lucas T, Páramo C, Picó A, Lucas A, Halperin I, Obiols G, Astorga R. Acromegaly Quality of Life Questionnaire (ACROQOL) a new health-related quality of life questionnaire for patients with acromegaly: development and psychometric properties. Clin Endocrinol (Oxf). 2002 Aug;57(2):251-8. doi: 10.1046/j.1365-2265.2002.01597.x. PMID: 12153605. https://pubmed.ncbi.nlm.nih.gov/12153605
Badia X, Webb SM, Prieto L, Lara N. Acromegaly Quality of Life Questionnaire (AcroQoL). Health Qual Life Outcomes. 2004 Feb 27;2:13. doi: 10.1186/1477-7525-2-13. PMID: 14987332; PMCID: PMC404471. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC404471/
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2024 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024